(Q58615572)

title

New promise and hope for treating hereditary angioedema (English)

0 references

main subject

hereditary angioedema

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18447596%20AND%20SRC:MED&resulttype=core&format=json

18 May 2020

author name string

Sandra C Christiansen

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18447596%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Investigational Drugs

18 May 2020

language of work or name

English

0 references

publication date

30 April 2008

0 references

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18447596%20AND%20SRC:MED&resulttype=core&format=json

18 May 2020

volume

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18447596%20AND%20SRC:MED&resulttype=core&format=json

18 May 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18447596%20AND%20SRC:MED&resulttype=core&format=json

18 May 2020

page(s)

697-706

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18447596%20AND%20SRC:MED&resulttype=core&format=json

Post-Traumatic Osteopenia: A Quantitative Study of the Bone Mineral Mass in the Femur Following Fracture of the Tibia in Man Using Americium-241 as a Photon Source

18 May 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.5.697

Hereditary angioedema: Safety of long-term stanozolol therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.5.697

Hepatocellular adenomas in patients taking danazol for hereditary angio-oedema

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.5.697

Adverse effects of danazol prophylaxis on the lipid profiles of patients with hereditary angioedema.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.5.697

Characterisation of a new C1 inhibitor mutant in a patient with hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.5.697

A BIOCHEMICAL ABNORMALITY IN HEREDIATRY ANGIONEUROTIC EDEMA: ABSENCE OF SERUM INHIBITOR OF C' 1-ESTERASE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.5.697

Replacement therapy in hereditary angioedema. Successful treatment of two patients with fresh frozen plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.5.697

Treatment of hereditary angioedema

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.5.697

Treatment of 193 episodes of laryngeal edema with C1 inhibitor concentrate in patients with hereditary angioedema

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.5.697

C1-inhibitor: an anti-inflammatory reagent with therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.5.697

Treatment with C1 inhibitor concentrate in abdominal pain attacks of patients with hereditary angioedema

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.5.697

Long-term prophylaxis with C1-inhibitor (C1 INH) concentrate in patients with recurrent angioedema caused by hereditary and acquired C1-inhibitor deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.5.697

Safety and efficacy of pasteurized C1 inhibitor concentrate (Berinert P) in hereditary angioedema: a review. jean.de.serres@aventis.com

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.5.697

Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.5.697

A randomized, controlled trial to study the efficacy and safety of C1 inhibitor concentrate in treating hereditary angioedema

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.5.697

Recent advances in the use of C1 inhibitor as a therapeutic agent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.5.697

Nanofiltration of plasma-derived biopharmaceutical products

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.5.697

N- and O-glycans of recombinant human C1 inhibitor expressed in the milk of transgenic rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.5.697

Recombinant human C1-inhibitor in the treatment of acute angioedema attacks.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.5.697

Prekallikrein activation and high-molecular-weight kininogen consumption in hereditary angioedema

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.5.697

Demonstration of modified inactive first component of complement (C1) inhibitor in the plasmas of C1 inhibitor-deficient patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.5.697

Detection of active kallikrein in induced blister fluids of hereditary angioedema patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.5.697

The pathogenesis of hereditary angioedema

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.5.697

DX-88 and HAE: a developmental perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.5.697

Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.5.697

Critical role of kallikrein in hereditary angioedema pathogenesis: a clinical trial of ecallantide, a novel kallikrein inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.5.697

Hoe 140 a new potent and long acting bradykinin-antagonist: in vitro studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.5.697

Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.5.697

Novel pharmacotherapy of acute hereditary angioedema with bradykinin B2-receptor antagonist icatibant

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.5.697

Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.5.697

Hereditary angioedema: a decade of human C1-inhibitor concentrate therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.5.697

Modern plasma fractionation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.5.697

Self-administration of C1-inhibitor concentrate in patients with hereditary or acquired angioedema caused by C1-inhibitor deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.5.697

10.1517/13543784.17.5.697

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18447596%20AND%20SRC:MED&resulttype=core&format=json

18 May 2020

1 reference